How have CASBF shares performed in 2024?

CanSino Biologics' stock was trading at C$2.95 at the beginning of 2024. Since then, CASBF stock has decreased by 4.1% and is now trading at C$2.83. View the best growth stocks for 2024 here .

How do I buy shares of CanSino Biologics?

Shares of CASBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:CASBF

CanSino Biologics (CASBF) Stock Price, News & Analysis

→ Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad)

Free CASBF Stock Alerts

C$2.83

0.00 (0.00%)

(As of 05/31/2024 ET)

Compare

Today's Range: C$2.83
▼
C$2.83
50-Day Range: C$1.86
▼
C$2.83
52-Week Range: C$1.86
▼
C$5.41

Volume: N/A
Average Volume: 1,794 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Short Interest

Get CanSino Biologics alerts:

Ad Wealthpin Pro

Trump’s Gift Could Unleash $51 Billion in New Wealth

In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.

You just have to make this simple move before July 30, 2024.

About CanSino Biologics

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

CASBF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CASBF Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive CASBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CanSino Biologics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: OTCMKTS:CASBF
CUSIP: N/A
CIK: N/A
Web: www.cansinotech.com
Phone: 400-922-2099
Fax: N/A
Employees: 1,494
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Xuefeng Yu Ph.D. (Age 59)
Co-Founder, Executive Chairman, CEO & GM
Dr. Tao Zhu Ph.D. (Age 51)
Co-Founder, Deputy GM & Chief Scientific Officer
Dr. Dongxu Qiu MBA (Age 64)
Ph.D., Co-Founder, Executive VP & Deputy GM
Dr. Shou-Bai Chao Ph.D. (Age 60)
COO, Deputy GM & Executive Director
Ms. Jing Wang (Age 43)
Chief Commercial Officer, Deputy GM & Executive Director
Mr. Chunlin Xin
Senior Director of New Technology Department
Mr. Yonghui Wu
Vice President of Marketing
Mr. Jin Cui (Age 37)
Board Secretary
Mr. Ming King Chiu FCIS (Age 47)
FCS, Joint Company Secretary

Key Competitors

View All Competitors

CASBF Stock Analysis - Frequently Asked Questions

How have CASBF shares performed in 2024?: CanSino Biologics' stock was trading at C$2.95 at the beginning of 2024. Since then, CASBF stock has decreased by 4.1% and is now trading at C$2.83.
View the best growth stocks for 2024 here.
How do I buy shares of CanSino Biologics?: Shares of CASBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CASBF) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial